Anne L Chang, MD | UniHealth

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

1 plan · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Sort by

Plans whose provider directory lists this clinician

DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A74696 · Current

Licensed to practise in California · since 2001 · expires 2026-12-31 · Harvard Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$86,418

Medicare paid this office $86,418 for 224 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	128	$26,426	$86
Short return visit (20+ min)	133	$12,317	$55
Destruction of precancer skin growth, 1 growth	130	$9,659	$45
Destruction of precancer skin growth, 15 or more growths	41	$5,732	$88
Destruction of skin growth, 1-14 growths	55	$5,111	$62

See all 13 services

Sort by

Every Original Medicare service billed

Return visit (30+ min)	128	$26,426	$86
Short return visit (20+ min)	133	$12,317	$55
Destruction of precancer skin growth, 1 growth	130	$9,659	$45
Destruction of precancer skin growth, 15 or more growths	41	$5,732	$88
Destruction of skin growth, 1-14 growths	55	$5,111	$62
Long return visit (40+ min)	16	$3,101	$129
Punch biopsy, first skin growth	64	$2,392	$30
New patient visit (45+ min)	18	$2,243	$125
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm	13	$2,154	$154
Destruction of precancer skin growth, 2-14 growths	128	$2,128	$2
Biopsy of related skin growth, first growth	47	$1,645	$25
Biopsy of related skin growth, each additional growth	34	$1,546	$20
Punch biopsy, each additional skin growth	18	$544	$23

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Melanoma (skin cancer) excision	22	More than 76% of doctors who do this
Removal of skin lesions	523	More than 87% of doctors who do this
Removal or shaving of skin growth	1-10	None
Skin biopsy	154	More than 81% of doctors who do this

Who their Medicare patients are

224 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 14% · Women 52% · Also on Medicaid 12% · Health risk score 1.34. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 54% · Diabetes 22% · Coronary heart disease 22% · Chronic kidney disease 22% · Cancer 22% · Atrial fibrillation 19% · Depression 14% · Heart failure 13% · COPD 8% · Stroke 6% · Dementia 5%.

The office billed $427,478, Medicare allowed $113,145 and paid $86,418; for 2,465 services of 41 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	224	2,465	75	1.34	$427,478	$86,418
2023	246	2,633	75	1.45	$458,048	$93,885
2022	199	1,792	75	1.36	$273,847	$55,731
2021	200	1,728	75	1.27	$292,747	$58,798
2020	194	1,233	75	1.53	$194,020	$37,114
2019	196	2,067	76	1.53	$200,037	$50,786
2018	194	1,991	75	1.32	$194,726	$54,698
2017	198	1,765	74	1.32	$188,954	$55,510
2016	207	1,584	73	1.36	$164,001	$47,283
2015	211	1,529	73	1.17	$162,245	$44,862
2014	191	1,346	71	1.19	$140,940	$37,137
2013	146	980	71	1.16	$89,407	$24,201

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 15 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	164	$30,882	$85
Destruction of precancer skin growth, 1 growth	130	$9,903	$45
Short return visit (20+ min)	116	$9,469	$57
Destruction of precancer skin growth, 15 or more growths	50	$7,724	$93
Destruction of skin growth, 1-14 growths	58	$4,746	$62
Long return visit (40+ min)	16	$4,447	$131
Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm	22	$3,302	$150
Punch biopsy, first skin growth	68	$2,963	$33
New patient visit (45+ min)	24	$2,899	$121
Biopsy of related skin growth, first growth	78	$2,759	$25
Destruction of precancer skin growth, 2-14 growths	117	$2,239	$2
Biopsy of related skin growth, each additional growth	44	$2,068	$20
Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm	11	$1,008	$92
Punch biopsy, each additional skin growth	26	$1,002	$24
New patient visit (30+ min)	19	$797	$42

2022: 13 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	102	$16,530	$82
Short return visit (20+ min)	110	$8,897	$52
Destruction of precancer skin growth, 1 growth	101	$6,888	$40
Destruction of skin growth, 1-14 growths	53	$3,575	$56
Long return visit (40+ min)	16	$3,194	$123
Destruction of precancer skin growth, 15 or more growths	30	$2,945	$80
Punch biopsy, first skin growth	47	$1,780	$30
Destruction of precancer skin growth, 2-14 growths	92	$1,486	$2
New patient visit (45+ min)	13	$1,449	$111
Biopsy of related skin growth, first growth	55	$1,381	$21
Biopsy of related skin growth, each additional growth	38	$1,195	$18
New patient visit (30+ min)	16	$845	$53
Punch biopsy, each additional skin growth	15	$439	$22

2021: 13 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	107	$20,278	$86
Short return visit (20+ min)	92	$7,067	$54
Destruction of precancer skin growth, 1 growth	101	$6,666	$41
Long return visit (40+ min)	29	$4,587	$118
Destruction of skin growth, 1-14 growths	53	$3,589	$56
Destruction of precancer skin growth, 15 or more growths	25	$2,776	$77
New patient visit (45+ min)	22	$2,590	$118
New patient visit (30+ min)	33	$2,135	$65
Biopsy of related skin growth, first growth	61	$1,898	$24
Punch biopsy, first skin growth	38	$1,448	$32
Destruction of precancer skin growth, 2-14 growths	91	$1,306	$2
Biopsy of related skin growth, each additional growth	32	$1,300	$19
Punch biopsy, each additional skin growth	11	$316	$21

2020: 13 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	92	$12,052	$71
Short return visit (20+ min)	94	$6,004	$42
Destruction of precancer skin growth, 1 growth	66	$3,691	$43
Destruction of precancer skin growth, 15 or more growths	25	$2,940	$95
Destruction of skin growth, 1-14 growths	41	$2,388	$56
Biopsy of related skin growth, first growth	44	$1,425	$26
Return visit (30+ min)	19	$1,171	$56
New patient visit (30+ min)	17	$950	$56
Destruction of precancer skin growth, 2-14 growths	63	$907	$2
Biopsy of related skin growth, each additional growth	20	$846	$19
Punch biopsy, first skin growth	14	$481	$32
Destruction of precancer skin growth, 1 growth	12	$315	$26
Destruction of precancer skin growth, 2-14 growths	11	$92	$2

2019: 18 services

Sort by

Original Medicare services billed in 2019

Return visit (30+ min)	72	$12,170	$70
Destruction of precancer skin growth, 1 growth	71	$6,173	$43
Short return visit (20+ min)	81	$4,965	$41
Destruction of skin growth, 1-14 growths	36	$3,537	$65
Destruction of precancer skin growth, 1 growth	64	$3,144	$36
Destruction of skin growth, 1-14 growths	38	$3,054	$61
Return visit (30+ min)	28	$2,643	$63
New patient visit (45+ min)	15	$1,749	$117
Destruction of precancer skin growth, 2-14 growths	64	$1,485	$2
Short return visit (20+ min)	20	$1,068	$44
Destruction of precancer skin growth, 15 or more growths	11	$957	$74
Biopsy of related skin growth, each additional growth	21	$809	$21
Destruction of precancer skin growth, 2-14 growths	52	$773	$2
Biopsy of related skin growth, first growth	28	$717	$20
Punch biopsy, first skin growth	16	$598	$33
Biopsy of related skin growth, first growth	28	$598	$20
Punch biopsy, first skin growth	13	$446	$34
Biopsy of related skin growth, each additional growth	13	$412	$21

2018: 18 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	65	$11,956	$68
Short return visit (20+ min)	83	$5,671	$43
Destruction of precancer skin growth, 1 growth	57	$4,501	$44
Destruction of skin growth, 1-14 growths	46	$3,272	$63
Destruction of precancer skin growth, 1 growth	53	$3,190	$39
Return visit (30+ min)	29	$2,943	$64
Destruction of precancer skin growth, 15 or more growths	21	$2,419	$93
Destruction of precancer skin growth, 15 or more growths	18	$2,399	$83
Biopsy of single growth of skin and/or tissue	48	$2,391	$31
Long return visit (40+ min)	18	$1,995	$100
Destruction of skin growth, 1-14 growths	20	$1,853	$58
New patient visit (45+ min)	15	$1,674	$112
Biopsy of each additional growth of skin and/or tissue	25	$1,427	$22
Biopsy of single growth of skin and/or tissue	42	$1,207	$24
Destruction of precancer skin growth, 2-14 growths	54	$1,035	$2
Destruction of precancer skin growth, 2-14 growths	49	$879	$2
Short return visit (20+ min)	15	$727	$40
Biopsy of each additional growth of skin and/or tissue	12	$315	$23

2017: 18 services

Sort by

Original Medicare services billed in 2017

Return visit (30+ min)	51	$11,771	$69
Short return visit (20+ min)	106	$7,078	$42
Return visit (30+ min)	34	$5,241	$67
Destruction of skin growth, 1-14 growths	44	$3,503	$61
Destruction of precancer skin growth, 1 growth	68	$3,389	$36
Destruction of precancer skin growth, 1 growth	42	$3,247	$46
Destruction of precancer skin growth, 15 or more growths	18	$2,478	$85
Destruction of precancer skin growth, 15 or more growths	21	$2,416	$83
Biopsy of single growth of skin and/or tissue	56	$2,340	$30
New patient visit (45+ min)	17	$1,956	$115
Biopsy of single growth of skin and/or tissue	42	$1,702	$30
Destruction of skin growth, 1-14 growths	19	$1,505	$68
Biopsy of each additional growth of skin and/or tissue	21	$1,204	$21
Short return visit (20+ min)	20	$1,132	$44
New patient visit (30+ min)	12	$743	$62
Destruction of precancer skin growth, 2-14 growths	63	$735	$2
Biopsy of each additional growth of skin and/or tissue	16	$672	$22
Destruction of precancer skin growth, 2-14 growths	37	$569	$2

2016: 15 services

Sort by

Original Medicare services billed in 2016

Short return visit (20+ min)	131	$10,502	$44
Return visit (30+ min)	30	$6,664	$66
Destruction of precancer skin growth, 1 growth	81	$5,392	$42
Return visit (30+ min)	27	$3,785	$69
Destruction of skin growth, 1-14 growths	39	$3,560	$64
Biopsy of single growth of skin and/or tissue	60	$2,106	$30
Short return visit (20+ min)	27	$1,767	$45
Destruction of precancer skin growth, 1 growth	21	$1,419	$46
Destruction of precancer skin growth, 15 or more growths	11	$1,341	$84
Biopsy of single growth of skin and/or tissue	26	$1,281	$37
Destruction of precancer skin growth, 2-14 growths	70	$1,137	$2
Biopsy of each additional growth of skin and/or tissue	15	$728	$23
New patient visit (30+ min)	11	$685	$62
Biopsy of each additional growth of skin and/or tissue	13	$499	$23
Destruction of precancer skin growth, 2-14 growths	16	$197	$2

2015: 12 services

Sort by

Original Medicare services billed in 2015

Short return visit (20+ min)	166	$11,719	$43
Return visit (30+ min)	39	$6,770	$66
Destruction of precancer skin growth, 1 growth	95	$5,348	$40
Destruction of skin growth, 1-14 growths	49	$3,925	$59
Biopsy of single growth of skin and/or tissue	86	$3,889	$34
Destruction of precancer skin growth, 15 or more growths	23	$3,053	$87
Biopsy of each additional growth of skin and/or tissue	30	$1,583	$23
Destruction of skin growth, 15 or more growths	19	$1,572	$83
New patient visit (45+ min)	13	$1,387	$107
Destruction of precancer skin growth, 2-14 growths	82	$1,132	$2
New patient visit (30+ min)	16	$950	$59
Short return visit (20+ min)	22	$932	$42

2014: 10 services

Sort by

Original Medicare services billed in 2014

Short return visit (20+ min)	147	$11,308	$42
Return visit (30+ min)	31	$5,183	$66
Destruction of precancer skin growth, 1 growth	78	$4,656	$37
Destruction of skin growth, 1-14 growths	42	$3,461	$57
Biopsy of single growth of skin and/or tissue	73	$2,841	$30
Destruction of skin growth, 15 or more growths	25	$2,113	$73
Destruction of precancer skin growth, 2-14 growths	68	$1,160	$2
Biopsy of each additional growth of skin and/or tissue	23	$820	$22
New patient visit (30+ min)	11	$675	$61
New patient visit (15+ min)	12	$413	$34

2013: 7 services

Sort by

Original Medicare services billed in 2013

Short return visit (20+ min)	132	$9,538	$40
Destruction of precancer skin growth, 1 growth	64	$3,923	$40
Destruction of skin growth, 1-14 growths	43	$2,932	$51
Biopsy of single growth of skin and/or tissue	44	$1,641	$29
Destruction of precancer skin growth, 2-14 growths	57	$1,618	$4
Return visit (30+ min)	11	$1,246	$57
Biopsy of each additional growth of skin and/or tissue	12	$533	$22

Medicaid work

$954 in 2023

Medicaid paid $954 for 26 billed services this clinician did in 2023, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2023

Return visit (30+ min)	26	$954

Sort by

Medicaid work by year

2023	26	1	13	$954
2022	12	1	12	$508

See the largest Medicaid services in earlier years

2022

Sort by

Largest Medicaid services in 2022

Short return visit (20+ min)	12	$508

Drugs they prescribed that Part D paid

$626,764

Pharmacies billed $626,764 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 467) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

389 generic and 78 brand-name prescriptions · $626,764 in drug cost · 22 antibiotic prescriptions to 15 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Humira	14	$95,486	$6,820
Dupixent	17	$60,787	$3,576
Fluorouracil	32	$3,416	$107
Clindamycin Phosphate	34	$1,213	$36
Metronidazole	17	$949	$56

See all 13 drugs

Sort by

Every Part D drug this clinician prescribed

Humira	14	$95,486	$6,820
Dupixent	17	$60,787	$3,576
Fluorouracil	32	$3,416	$107
Clindamycin Phosphate	34	$1,213	$36
Metronidazole	17	$949	$56
Fluocinonide	21	$899	$43
Ketoconazole	44	$535	$12
Triamcinolone Acetonide	39	$525	$13
Valacyclovir	14	$480	$34
Doxycycline Hyclate	12	$448	$37
Ciclopirox	12	$383	$32
Hydrocortisone	20	$82	$4
Minoxidil	11	$79	$7

Year by year

Sort by

Part D prescribing by year

2024	467	136	0% (0)	17%	$626,764
2023	512	160	0% (0)	15%	$562,848
2022	403	119	None	11%	$464,860
2021	409	117	0% (0)	14%	$471,183
2020	314	96	None	13%	$318,276
2019	222	69	0% (0)	10%	$60,345
2018	291	93	0% (0)	24%	$458,849
2017	353	102	None	27%	$670,991
2016	381	110	None	28%	$492,719
2015	408	109	None	33%	$365,292
2014	451	107	None	None	$376,520
2013	329	87	None	None	$422,982

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 17 drugs

Sort by

Part D drugs prescribed in 2023

Erivedge	16	$207,211	$12,951
Fluorouracil	43	$3,261	$76
Acitretin	18	$2,210	$123
Desonide	12	$1,316	$110
Fluocinonide	29	$1,288	$44
Clindamycin Phosphate	25	$1,120	$45
Clobetasol Propionate	11	$851	$77
Ketoconazole	44	$812	$18
Triamcinolone Acetonide	56	$796	$14
Metronidazole	11	$702	$64
Nystatin	16	$501	$31
Ciclopirox	13	$368	$28
Hydroxyzine	14	$319	$23
Ciclopirox	11	$186	$17
Cephalexin	11	$168	$15
Gabapentin	14	$148	$11
Finasteride	18	$138	$8

2022: 15 drugs

Sort by

Part D drugs prescribed in 2022

Erivedge	28	$342,150	$12,220
Doxycycline Hyclate	11	$2,091	$190
Fluorouracil	15	$1,348	$90
Ketoconazole	51	$1,265	$25
Fluocinonide	18	$1,121	$62
Clindamycin Phosphate	15	$982	$65
Desonide	11	$695	$63
Triamcinolone Acetonide	30	$493	$16
Ciclopirox	15	$365	$24
Clobetasol Propionate	12	$331	$28
Gabapentin	17	$243	$14
Methotrexate	13	$161	$12
Hydroxyzine	12	$161	$13
Hydrocortisone	12	$103	$9
Finasteride	11	$61	$6

2021: 10 drugs

Sort by

Part D drugs prescribed in 2021

Erivedge	30	$374,091	$12,470
Fluorouracil	26	$1,997	$77
Desonide	21	$1,720	$82
Fluocinonide	26	$1,686	$65
Ketoconazole	41	$1,308	$32
Triamcinolone Acetonide	38	$654	$17
Clobetasol Propionate	15	$606	$40
Ciclopirox	13	$302	$23
Gabapentin	19	$233	$12
Hydrocortisone	12	$95	$8

2020: 9 drugs

Sort by

Part D drugs prescribed in 2020

Erivedge	14	$173,663	$12,405
Odomzo	11	$127,547	$11,595
Fluorouracil	22	$2,431	$110
Fluocinonide	26	$1,450	$56
Desonide	11	$1,250	$114
Ketoconazole	30	$974	$32
Triamcinolone Acetonide	34	$396	$12
Quetiapine	11	$72	$7
Trazodone	11	$31	$3

2019: 5 drugs

Sort by

Part D drugs prescribed in 2019

Fluocinonide	19	$895	$47
Ketoconazole	19	$539	$28
Doxycycline Hyclate	13	$523	$40
Triamcinolone Acetonide	23	$466	$20
Hydrocortisone	13	$101	$8

2018: 7 drugs

Sort by

Part D drugs prescribed in 2018

Erivedge	35	$419,702	$11,991
Desonide	11	$1,254	$114
Fluocinonide	17	$803	$47
Ketoconazole	28	$790	$28
Triamcinolone Acetonide	40	$565	$14
Doxycycline Hyclate	12	$321	$27
Mupirocin	11	$58	$5

2017: 10 drugs

Sort by

Part D drugs prescribed in 2017

Erivedge	44	$587,831	$13,360
Calcipotriene	15	$5,733	$382
Fluocinonide	28	$1,875	$67
Desonide	12	$1,755	$146
Doxycycline Hyclate	20	$1,017	$51
Triamcinolone Acetonide	39	$666	$17
Clindamycin Phosphate	12	$653	$54
Ketoconazole	26	$489	$19
Valacyclovir	12	$469	$39
Gabapentin	15	$294	$20

2016: 12 drugs

Sort by

Part D drugs prescribed in 2016

Erivedge	39	$426,979	$10,948
Clobetasol Propionate	11	$3,516	$320
Fluocinonide	26	$2,951	$114
Fluorouracil	11	$1,652	$150
Metronidazole	11	$1,639	$149
Desonide	13	$1,526	$117
Valacyclovir	16	$1,111	$69
Triamcinolone Acetonide	48	$894	$19
Methotrexate	13	$845	$65
Clindamycin Phosphate	11	$814	$74
Ketoconazole	29	$411	$14
Hydrocortisone	16	$120	$8

2015: 11 drugs

Sort by

Part D drugs prescribed in 2015

Erivedge	19	$182,706	$9,616
Calcipotriene	19	$8,215	$432
Desonide	32	$7,981	$249
Clobetasol Propionate	17	$4,020	$236
Fluorouracil	14	$3,897	$278
Fluocinonide	41	$3,456	$84
Econazole Nitrate	12	$2,787	$232
Hydroxychloroquine Sulfate	16	$2,459	$154
Valacyclovir	19	$902	$47
Ketoconazole	26	$882	$34
Triamcinolone Acetonide	43	$849	$20

2014: 14 drugs

Sort by

Part D drugs prescribed in 2014

Erivedge	14	$135,499	$9,678
Enbrel	13	$70,743	$5,442
Imiquimod	21	$10,486	$499
Calcipotriene	18	$9,877	$549
Desonide	23	$3,952	$172
Fluocinonide	21	$1,687	$80
Triamcinolone Acetonide	65	$1,487	$23
Econazole Nitrate	16	$1,051	$66
Valacyclovir	21	$991	$47
Methotrexate	16	$868	$54
Ketoconazole	41	$770	$19
Clobetasol Propionate	18	$645	$36
Hydroxychloroquine Sulfate	15	$376	$25
Hydrocortisone	11	$76	$7

2013: 9 drugs

Sort by

Part D drugs prescribed in 2013

Erivedge	42	$340,178	$8,099
Enbrel	14	$58,385	$4,170
Desonide	11	$1,850	$168
Clindamycin Phosphate	20	$1,192	$60
Methotrexate	22	$766	$35
Valacyclovir	15	$701	$47
Ketoconazole	28	$547	$20
Triamcinolone Acetonide	21	$286	$14
Hydroxyzine	12	$126	$10

Money from drug and device companies

$20,923 in 2025

Sort by

Industry payments by year

2025	4	23	$17,652	$20,923
2024	3	13	$8,300	$10,538
2023	4	39	$13,892	$20,258
2020	4	5	$15,581	$15,604
2019	3	27	$10,925	$39,118

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Regeneron Pharmaceuticals	Libtayo	$12,889	12 payments Consulting for Libtayo · 2025-12-19 · $887 Consulting for Libtayo · 2025-12-19 · $4,435 Consulting for Libtayo · 2025-12-19 · $5,322 Travel for Libtayo · 2025-12-19 · $76 Meals for Libtayo · 2025-11-13 · $144 Travel for Libtayo · 2025-11-13 · $599 Meals for Libtayo · 2025-11-13 · $36 Meals for Libtayo · 2025-11-13 · $141 Travel for Libtayo · 2025-10-31 · $82 Travel for Libtayo · 2025-10-30 · $164 Travel for Libtayo · 2025-10-17 · $969 Travel for Libtayo · 2025-10-17 · $35
Abbvie	None	$4,857	7 payments Consulting · 2025-05-08 · $4,008 Meals · 2025-04-18 · $149 Travel · 2025-03-28 · $240 Meals · 2025-03-26 · $90 Travel · 2025-03-26 · $78 Travel · 2025-03-26 · $31 Travel · 2025-03-25 · $261
Sun Pharmaceutical Industries	Odomzo	$3,026	3 payments Consulting for Odomzo · 2025-08-14 · $1,500 Consulting for Odomzo · 2025-03-20 · $1,500 Meals · 2025-03-08 · $26
Galderma Laboratories L.P.	None	$150	1 payment Meals · 2025-03-07 · $150

See all 23 published payments

Sort by

Every published payment

Regeneron Pharmaceuticals	Consulting · 2025-12-19	Libtayo	$887
Regeneron Pharmaceuticals	Consulting · 2025-12-19	Libtayo	$4,435
Regeneron Pharmaceuticals	Consulting · 2025-12-19	Libtayo	$5,322
Regeneron Pharmaceuticals	Travel · 2025-12-19	Libtayo	$76
Regeneron Pharmaceuticals	Meals · 2025-11-13	Libtayo	$144
Regeneron Pharmaceuticals	Travel · 2025-11-13	Libtayo	$599
Regeneron Pharmaceuticals	Meals · 2025-11-13	Libtayo	$36
Regeneron Pharmaceuticals	Meals · 2025-11-13	Libtayo	$141
Regeneron Pharmaceuticals	Travel · 2025-10-31	Libtayo	$82
Regeneron Pharmaceuticals	Travel · 2025-10-30	Libtayo	$164
Regeneron Pharmaceuticals	Travel · 2025-10-17	Libtayo	$969
Regeneron Pharmaceuticals	Travel · 2025-10-17	Libtayo	$35
Sun Pharmaceutical Industries	Consulting · 2025-08-14	Odomzo	$1,500
Abbvie	Consulting · 2025-05-08	None	$4,008
Abbvie	Meals · 2025-04-18	None	$149
Abbvie	Travel · 2025-03-28	None	$240
Abbvie	Meals · 2025-03-26	None	$90
Abbvie	Travel · 2025-03-26	None	$78
Abbvie	Travel · 2025-03-26	None	$31
Abbvie	Travel · 2025-03-25	None	$261
Sun Pharmaceutical Industries	Consulting · 2025-03-20	Odomzo	$1,500
Sun Pharmaceutical Industries	Meals · 2025-03-08	None	$26
Galderma Laboratories L.P.	Meals · 2025-03-07	None	$150

See earlier years (2024, 2023, 2020, 2019)

2024: $10,538

Sort by

Payments by company in 2024

Sun Pharmaceutical Industries	Odomzo	$8,602	11 payments Travel for Odomzo · 2024-06-18 · $324 Consulting for Odomzo · 2024-06-15 · $5,000 Meals for Odomzo · 2024-06-15 · $92 Meals for Odomzo · 2024-06-15 · $65 Travel for Odomzo · 2024-06-15 · $63 Meals for Odomzo · 2024-06-15 · $38 Meals for Odomzo · 2024-06-15 · $38 Travel for Odomzo · 2024-06-14 · $150 Meals for Odomzo · 2024-06-14 · $115 Travel for Odomzo · 2024-05-23 · $1,117 Consulting for Odomzo · 2024-04-10 · $1,600
Galderma Laboratories L.P.	None	$1,700	1 payment Consulting · 2024-11-13 · $1,700
Abbvie	None	$236	1 payment Meals · 2024-06-26 · $236

2023: $20,258

Sort by

Payments by company in 2023

Galderma Laboratories L.P.	None	$14,993	30 payments Consulting · 2023-12-15 · $3,084 Consulting · 2023-12-15 · $3,084 Consulting · 2023-12-15 · $3,084 Travel · 2023-12-02 · $51 Meals · 2023-12-02 · $18 Meals · 2023-12-02 · $20 Meals · 2023-12-02 · $16 Meals · 2023-12-02 · $42 Travel · 2023-12-02 · $13 Travel · 2023-12-02 · $51 Travel · 2023-12-02 · $13 Meals · 2023-12-02 · $18 Meals · 2023-12-02 · $20 Meals · 2023-12-02 · $16 Meals · 2023-12-02 · $42 Travel · 2023-12-02 · $51 Meals · 2023-12-02 · $18 Meals · 2023-12-02 · $20 Meals · 2023-12-02 · $16 Meals · 2023-12-02 · $42 Travel · 2023-12-02 · $13 Travel · 2023-12-01 · $186 Travel · 2023-12-01 · $283 Travel · 2023-12-01 · $1,286 Travel · 2023-12-01 · $1,286 Travel · 2023-12-01 · $186 Travel · 2023-12-01 · $283 Travel · 2023-12-01 · $1,286 Travel · 2023-12-01 · $186 Travel · 2023-12-01 · $283
Sun Pharmaceutical Industries	Odomzo	$5,099	7 payments Consulting for Odomzo · 2023-08-19 · $4,640 Travel for Odomzo · 2023-08-19 · $281 Meals for Odomzo · 2023-08-19 · $40 Meals for Odomzo · 2023-08-19 · $20 Meals for Odomzo · 2023-08-19 · $41 Meals for Odomzo · 2023-08-19 · $64 Meals for Odomzo · 2023-08-19 · $12
Regeneron Healthcare Solutions	Libtayo	$151	1 payment Meals for Libtayo · 2023-12-01 · $151
Pfizer	Cibinqo	$15	1 payment Education for Cibinqo · 2023-04-12 · $15

2020: $15,604

Sort by

Payments by company in 2020

Merck Sharp & Dohme	None	$8,850	2 payments Consulting · 2020-05-22 · $1,500 Consulting · 2020-05-22 · $7,350
Sun Pharmaceutical Industries	Odomzo	$4,000	1 payment Honoraria for Odomzo · 2020-11-03 · $4,000
Regeneron Healthcare Solutions	Libtayo	$2,731	1 payment Consulting for Libtayo · 2020-03-05 · $2,731
EMD Serono	Bavencio	$23	1 payment Meals for Bavencio · 2020-03-10 · $23

2019: $39,118

Sort by

Payments by company in 2019

Galderma Laboratories L.P.	None	$25,494	2 payments Grant · 2019-10-18 · $15,296 Grant · 2019-01-04 · $10,197
Regeneron Pharmaceuticals	Libtayo	$12,354	13 payments Consulting for Libtayo · 2019-10-29 · $5,175 Consulting for Libtayo · 2019-10-29 · $3,450 Travel for Libtayo · 2019-10-29 · $107 Travel for Libtayo · 2019-10-26 · $324 Meals for Libtayo · 2019-10-26 · $50 Meals for Libtayo · 2019-10-26 · $25 Meals for Libtayo · 2019-10-26 · $60 Meals for Libtayo · 2019-10-26 · $25 Travel for Libtayo · 2019-10-20 · $147 Travel for Libtayo · 2019-10-20 · $136 Travel for Libtayo · 2019-10-07 · $519 Travel for Libtayo · 2019-10-07 · $35 Consulting for Libtayo · 2019-07-09 · $2,300
Merck Sharp & Dohme	Keytruda	$1,271	12 payments Travel for Keytruda · 2019-02-14 · $146 Meals for Keytruda · 2019-02-14 · $20 Meals for Keytruda · 2019-02-14 · $26 Meals for Keytruda · 2019-02-14 · $48 Travel for Keytruda · 2019-02-14 · $72 Meals for Keytruda · 2019-02-14 · $12 Meals for Keytruda · 2019-02-13 · $15 Meals for Keytruda · 2019-02-13 · $157 Travel for Keytruda · 2019-02-13 · $167 Meals for Keytruda · 2019-02-13 · $17 Travel for Keytruda · 2019-02-13 · $554 Travel for Keytruda · 2019-02-13 · $36

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Merck Sharp & Dohme Corporation · Open-Label Two Arm Study of Pembrolizumab for Unresectable Or Metastatic Cutaneous Basal Carcinoma · 2019	Their institution	$478,069
Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, Or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy · 2020	Their institution	$407,822
Merck Sharp & Dohme Corporation · Phase 2, Open-Label, Single Arm Study To Evaluate the Safety Andefficacy of Pembrolizumab in Participants With Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma R,M Cscc · 2019	Their institution	$236,330
Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1 (Pd-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma · 2020	Their institution	$224,808
Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, Or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy · 2019	Their institution	$187,822
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Pembrolizumab Versus Placebo As Adjuvant Therapy Following Surgery and Radiation of High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma La Cscc. · 2020	Their institution	$77,289
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Pembrolizumab Versus Placebo As Adjuvant Therapy Following Surgery and Radiation of High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma La Cscc. · 2019	Their institution	$65,215
Regeneron Pharmaceuticals, Inc. · A Phase 1 Study of Pre-Operative Cemiplimab (Regn2810), Administered Intralesionally, for Patients With Recurrent Cutaneous Squamous Cell Carcinoma (Cscc) · 2020	Their institution	$65,024
Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, Or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy · 2021	Their institution	$62,029
Merck Sharp & Dohme Corporation · Phase 2, Open-Label, Single Arm Study To Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma R,M Cscc · 2020	Their institution	$57,812
Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1 Pd-1, in Patients With Advanced Cutaneous Squamous Cell Carcinoma · 2019	Their institution	$37,970
Merck Sharp & Dohme Corporation · Phase 2, Open-Label, Single Arm Study To Evaluate the Safety Andefficacy of Pembrolizumab in Participants With Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma (R/M Cscc) · 2019	Their institution	$32,492
Regeneron Pharmaceuticals, Inc. · A Phase 2 Study of Regn2810, A Fully Human Monoclonal Antibody To Programmed Death-1 (Pd-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma · 2021	Their institution	$31,140
Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2020	Their institution	$19,584
Merck Sharp & Dohme Corporation · A Phase III, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Pembrolizumab Versus Placebo As Adjuvant Therapy Following Surgery and Radiation of High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma La Cscc. · 2021	Their institution	$14,775
Regeneron Pharmaceuticals, Inc. · A Phase 1 Study of Pre-Operative Cemiplimab Regn2810, Administered Intralesionally, for Patients With Recurrent Cutaneous Squamous Cell Carcinoma Cscc · 2019	Their institution	$14,400
Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2021	This clinician	$6,783
Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2020	This clinician	$5,538
Merck Sharp & Dohme Corporation · Phase 2, Open-Label, Single Arm Study To Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma R,M Cscc · 2021	Their institution	$5,147
Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2022	This clinician	$3,151
Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2023	This clinician	$2,899
Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2019	This clinician	$2,687
Regeneron Pharmaceuticals, Inc. · Libtayo Clinical Publication Program · 2024	This clinician	$2,356
F. Hoffmann-La Roche AG · A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients · 2022	This clinician	$1,350
Genentech, Inc. · Regisonic Bcc Bccns Disease Registry · 2019	Their institution	$753
Novartis Pharmaceuticals Corporation · A Randomized Investigator and Patient Blind Placebo Controlled Parallel Group First in Human and Proof of Concept Study To Evaluate the Safety Tolerability and Efficacy of Cll442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ Sccis · 2019	Their institution	$37

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1013049188
Licence: CA A74696California A74696: Current · expires 2026-12-31
Trained: Harvard Medical School, 1999
Group: Stanford Health Care
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207N00000X (207N00000X)
Mailing address: 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
NPI first listed: 2007-03-12
NPI last updated: 2024-04-16
NPI record certified: 2024-04-16

This is when the NPI record was last certified, not a medical board exam.